New study aims to predict breast cancer response to Pre-Surgery hormone therapy
NCT ID NCT06806930
First seen Feb 22, 2026 · Last updated May 17, 2026 · Updated 10 times
Summary
This study is for people with early-stage breast cancer (Stage I-III) who will receive hormone therapy before surgery. Researchers want to see how the cancer responds to this treatment and if they can predict the outcome using blood and tissue samples. Participants will be followed for 2 weeks to 1 year, depending on their treatment plan.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE I are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
George Washington-Medical Faculty Associates
RECRUITINGWashington D.C., District of Columbia, 20037, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.